



Biomaterialaletako Ikerkuntza Kooperatiboko Zentroa  
Centro de Investigación Cooperativa en Biomateriales

# THE MOLECULAR BASIS OF THE ACTIVATION OF FIBROBLAST GROWTH FACTORS BY GLYCOSAMINOGLYCANs

*FESTKOLLOQUIUM*


*on the occasion of the 85th Birthday of*

*Prof. Dr. rer. nat. Hans Paulsen, Hamburg 2007*















Biomaterialaletako Ikerkuntza Kooperatiboko Zentroa  
Centro de Investigación Cooperativa en Biomateriales


# THE MOLECULAR BASIS OF THE ACTIVATION OF FIBROBLAST GROWTH FACTORS BY GLYCOSAMINOGLYCANs

*FESTKOLLOQUIUM*


*on the occasion of the 85th Birthday of*

*Prof. Dr. rer. nat. Hans Paulsen, Hamburg 2007*

# Structure of heparin





# Structure and biology of heparan-sulphate glycosaminoglycans





# CHEMICAL STRUCTURE OF HEPARIN-HS

Uronic acid (1-4) glucosamine





<b>D-glucuronic</b>	<b>2-Sulfate</b>	<b>N-Sulfate</b>
<b>L-iduronic</b>	<b>2-Sulfate</b>	<b>6-Sulfate</b> <b>N-acetyl</b> <b>3-Sulfate</b> <b>free amine</b>


Domain	Major sequence	Exclusive sequence
NA	GlcA - GlcNAc	GlcNH <sub>2</sub>
NS	GlcA / IdoA - 6S-GlcNS	2S-IdoA , 3S-GlcN
NA/NS	NA + NS	




# THREE DIMENSIONAL STRUCTURE OF HS-GAGs




# The interaction of heparin with AT III



# The interaction of heparin with AT III




## Structure of the AT III binding pentasaccharide





# Characteristics of selected heparin-binding proteins

Heparin-binding protein	Physiological/Pathological role	$K_d$	Characteristics of heparin binding		
			Oligosaccharide size	Sequence features	Function
<i>proteases/esterases</i>					
AT III	coagulation cascade serpin	ca. 20 nM	5-mer	GlcNS6S3S	enhances
SLPI	inhibits elastase and cathepsin G	ca. 6 nM	12-mer to 14-mer	IS	enhances
C1 INH	inhibits C1 esterase	ca. 100 nM	-	HS	enhances
VCP	protects host cell from complement	nM	-		unclear
<i>growth factors</i>					
<b>FGF-1</b>	cell proliferation, differentiation, morphogenesis, and angiogenesis	nM	4-mer to 6-mer	IdoA2S-GlcNS6S	activates signal transduction
<b>FGF-2</b>	(same as FGF-1)	nM	4-mer to 6-mer	IdoA2S-GlcNS	(same as FGF-1)
<i>chemokines</i>					
PF-4	inflammation and wound healing	nM	12-mer	HS/LS/HS	inactivates heparin
IL-8	pro-inflammatory cytokine	ca. 6 $\mu$ M	18-mer to 20-mer	HS/LS/HS	promotes
SDF-1 $\alpha$	pro-inflammatory mediator	ca. 20 nM	12-mer to 14-mer	HS	localizes
<i>lipid-binding proteins</i>					
Annexin II	receptor for TPA and plasminogen, CMV and tenascin C	ca. 30 nM	4-mer to 5-mer	HS	unclear
Annexin V	anticoagulant activity; influenza and hepatitis B viral entry	ca. 20 nM	8-mer	HS	assembles
ApoE	lipid transport; AD risk factor	ca. 100 nM	8-mer	HS	localizes
<i>pathogen proteins</i>					
HIV-1 gp120	viral entry	0.3 $\mu$ M	10-mer	HS	inhibits
CypA	viral localization and entry	-	-	-	inhibits
Tat	transactivating factor, primes cells for HIV infection	ca. 70 nM	6-mer	HS	antagonizes
HSV gB and gC	viral entry into cell	-	-	-	inhibits
HSV gD	viral entry and fusion	-	-	GlcNH <sub>2</sub> 3S	inhibits
Dengue virus envelope protein	viral localization	ca. 15 nM	10-mer	HS	inhibits
Malaria CS protein	sporozoite attachment to hepatocytes	ca. 40 nM	10-mer	HS	inhibits
<i>adhesion proteins</i>					
selectins	adhesion, inflammation, and metastasis	$\mu$ M	$\geq$ 4-mer	HS with GlcNH <sub>2</sub>	blocks
vitronectin	cell adhesion and migration	$\mu$ M	-	-	removes
fibronectin	adhesion and traction	$\mu$ M	8-mer to 14-mer	HS with GlcNS	reorganizes
HB-GAM	neurite outgrowth in development	ca. 10 nM	16-mer to 18-mer	HS	mediates
AP	in amyloid plaque	$\mu$ M	4-mer	HS	assembles


# Schematic Diagram of a Ternary Complex FGF-GAG-FGFR



# FGF Oligomerization and Ternary Complexes






J. SCHLESSINGER, *Mol. Cell.*, 2000,  
6, 743









L. PELLEGRINI, *Nature*, 2000, 407,  
1029

A. D. DIGABRIELE, et al, *Nature*, 1998,  
393, 812




# Heparin-like oligosaccharides


F E D C B A







# Retrosynthetic Analysis



# Solid phase synthesis of regular region hexasaccharide




# NMR Studies of the regular region hexasaccharide Conformation of the iduronate units





Conformational populations

	$^1C_4: ^2S_O$
IdoA-1	70:30
IdoA-3	69:31
IdoA-5	72:28




# Molecular dynamics (PME) of the regular region hexasaccharide




J. Angulo et al.

Chem. Commun. 2003, 1512-1513


## $^1\text{C}_4$ Conformers





## $^2\text{S}_0$ Conformers



# NMR Studies of the Regular Region Hexasaccharide





Interglycosidic NOEs




Pair	Distance (Å)	$\tau_{\text{isotropic}}$ (ps)
H1 - H2	2.4	700
H2 - H4	2.5	1300


# Mitogenic activity of the regular region oligosaccharides




# Mitogenic activity




Regular hexasaccharide



Regular octasaccharide





Asymmetric hexasaccharide




Asymmetric octasaccharide

# Mitogenic Activity



# Sedimentation equilibrium curves of FGF-1 in the presence of synthetic oligosaccharides



A: FGF-1

(Mw = 16640 ± 885)

B: FGF-1+ LMWH

(Mw = 30180 ± 1940)


C: FGF-1 + Hexasaccharide

(Mw = 18500 ± 540)

D: FGF-1 + Octasaccharide



(Mw = 19130 ± 790)

# FGF1 activation by synthetic heparin oligosaccharides



ChemBioChem, 2004, 5, 55-61


- LM heparin 3000
- ▲ Asymmetric distribution
- Regular region
- ◆ 20H
- ▼ 60H




Regular region






20H


60H



O4  
O1









FGF-1 Activator




FGF-2 Inhibitor




LOW BINDING



HIGH BINDING





## SPR: FGF-1 Binding Constants




# ASSIGNMENT of 3D-experiments


HNCA



HSQC-NOESY  $^{15}\text{N}-^1\text{H}$



A. Canales et al. PEBS J., 2006, 273, 4716-4727




# Stereoview of the best fit superpositions of the structure of asymmetric hexasaccharide-bound FGF-1



**Superposition of 20 structures  
rmsd=0.94 Å  
1432 NOEs : 260 sequencial  
667 medium range  
505 long range**

# BINDING SITE MAPPING


$^{15}\text{N}$ - $^1\text{H}$ -HSQC



Binding site



# The flexibility of the complex



Element	$\Delta S^2$
LOOP 1	0.16
SHEET 4	0.16
TURN 3	0.26
SHEET 5	0.14
SHEET 6	0.13
LOOP 2	0.28
TURN 6	-0.16
SHEET 10	0.18
TURN 7	0.34
SHEET 11	0.20
LOOP 4	0.12
SHEET 12	0.14








Conformational entropy loss amounts to ca. 56 kJ/mol

A. Canales, 2004

A. Canales *J. Biomol. NMR*, 2006, 35, 225-239


# The structure of the bound hexasaccharide

<sup>13</sup>C-filtered- NOESY  
CHAIR-BOAT  
EQUILIBRIUM IN THE  
BOUND STATE




A. Canales et al. J. Am. Chem. Soc. 2005, 127, 5778-5779

## Dynamics of the hexasaccharide within the Complex



# The Complex: NOE INFORMATION



## AUTODOCK

First docking run:

Global search for the binding site

Second step:


local search of the binding site

(rigid ligand)

Third step:

local search of the binding site

(flexible ligand)



## ACKNOWLEDGMENTS

### Synthesis (IIQ)

José L. de Paz  
Rafael Ojeda  
Ricardo Lucas  
Niels-Christian Reichardt  
Olimpia Terentí

### Structure (IIQ, CIB)

Pedro M. Nieto  
Jesús Angulo  
Jesús Jiménez-Barbero  
Angeles Canales

### Biological Activity (CIB)

Guillermo Giménez-Gallego  
Rosa M. Lozano

### Financial support

DGCYT (PB96-0820)  
DGCYT (BQU02-03734)  
Fundación Ramón Areces  
Fundación Francisco Cobos